

Supporting Information

Bromo-cyclobutenaminones as new covalent MurA inhibitors

David J. Hamilton^{a,b}, Péter Ábrányi-Balogh^b, Aaron Keeley^b, László Petri^b, Martina Hrast^c, Tímea Imre^d, Maikel Wijtmans^a, Stanislav Gobec^c, Iwan J. P. de Esch^a, and György Miklós Keserű^{b,*}

^a Division of Medicinal Chemistry, Amsterdam Institute of Molecular and Life Sciences (AIMMS), Faculty of Science, Vrije Universiteit Amsterdam, De Boelelaan 1108, 1081 HZ Amsterdam, The Netherlands.

^b Medicinal Chemistry Research Group, Research Centre for Natural Sciences, Magyar tudósok krt 2, H-1117 Budapest, Hungary

^c Faculty of Pharmacy, University of Ljubljana, Aškerčeva 7, SI-1000 Ljubljana, Slovenia

^d MS Metabolomics Research Group, Research Centre for Natural Sciences, Magyar tudósok krt 2, H-1117 Budapest, Hungary

* corresponding author: keseru.gyorgy@ttk.mta.hu


Table of contents

Table S1. Results of time-dependent IC ₅₀ measurements of 17b	2
Figure S1. The MS/MS spectrum of 17b modified MurA enzyme peptide [104-120] together with the annotation of the peaks.....	2
NMR, LC-MS and HRMS data of key compound 17a	3



Table S1. Results of time-dependent IC₅₀ measurements of 17b



Preincubation time	IC ₅₀ (μ M)
0 min	356 \pm 29
15 min	149 \pm 15
30 min	128 \pm 10

Figure S1. The MS/MS spectrum of 17b modified MurA enzyme peptide [104-120] together with the annotation of the peaks



NMR, LC-MS and HRMS data of key compound 17a





#.1 Ret.Time:Averaged 4.610-4.630(Scan#:462-464)
 BG Mode:Calc 4.480<->4.980(449<->499)
 Mass Peaks:8 Base Peak:310.00(406224) Polarity:Pos Segment1 - Event1

